# US 2025/0084137 A1 · Methods and compositions for treating and/or preventing a disease or disorder associated with abnormal level and/or activity of the ifp35 family of proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0084137 A1
- Document ID: US20250084137A1
- Status: Published application
- Kind: A1
- Application number: 18/899,627
- Filed: 2024-09-27
- Published: 2025-03-13
- Earliest claimed: 2014-08-22
- Assignees: Guangzhou Inno-Enmai Biomedical Technology Co., Ltd
- Applicants: Guangzhou Inno-Enmai Biomedical Technology Co., Ltd
- Inventors: Yingfang LIU; Huanhuan LIANG; Juan SHEN; Zhikai XIAHOU
- Web page: https://patentgrep.com/patent/US20250084137A1

## CPC

- C07K 14/47: from mammals
- A61K 39/0011: {Cancer antigens}
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 16/18: against material from animals or humans
- C07K 16/24: against cytokines, lymphokines or interferons
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- G01N 33/68: involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/567: Framework region [FR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C12N 2310/11: Antisense
- G01N 2500/04: Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
- G01N 2500/20: cell-free systems
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to methods and compositions for treating and/or preventing a disease or disorder associated with abnormally high level of the IFP35 family of proteins, including IFP35 and NMI, methods and compositions for diagnosis, prognosis or treatment monitoring of a disease or disorder associated with abnormally high level of the IFP35 family of proteins, including IFP35 and NMI, and methods and compositions for identifying a modulator of the IFP35 family of proteins, including IFP35 and NMI.

## Claims

### Claim 1

A method for treating and/or preventing a disease or disorder associated with abnormally high level and/or activity of Interferon-induced Protein 35 kD (IFP35) and/or N-Myc-interacting protein (NMI) in a subject in need thereof, comprising administering to the subject an effective amount of an agent that prevents or reduces production and/or activity of IFP35 and/or NMI in the subject;
wherein the disease or disorder associated with abnormally high level and/or activity of IFP35 and/or NMI is associated with excessive immune response or excessive inflammatory response.

### Claim 2 (depends on 1)

The method of claim 1, wherein the disease or disorder associated with abnormally high level and/or activity of IFP35 and/or NMI is selected from the group comprising inflammation, infection, sepsis, organ damage, and autoimmune disease.

### Claim 3 (depends on 1)

The method of claim 1, wherein the agent comprises a small molecule or a micromolecule polypeptide that inhibits or reduces the expression and/or activity of IFP35 and/or NMI; or
wherein the agent comprises an antibody or antigen binding fragment thereof that inhibits or reduces the expression and/or activity of IFP35 and/or NMI; or
wherein the agent comprises a polynucleotide targeting a gene encoding IFP35 and/or NMI; or
wherein the agent comprises an antisense RNA targeting the gene encoding IFP35 and/or NMI; or
wherein the agent comprises a molecule that inhibits or reduces the aggregation of IFP35 and/or NMI; or
wherein the agent comprises a molecule that inhibits or reduces the expression and/or activity of an interferon, thereby inhibiting or reducing the expression and/or activity of IFP35 and/or NMI; or
wherein the agent comprises a molecule that inhibits or reduces the secretion of IFP35 and/or NMI; or
wherein the agent comprises a molecule that inhibits or reduces the interaction between IFP35 and/or NMI and an intracellular receptor of IFP35 and/or NMI; or
wherein the agent comprises a molecule that inhibits or reduces the interaction between IFP35 and/or NMI and a cell surface receptor of IFP35 and/or NMI; or
wherein the agent comprises a molecule that prevents or reduces the production and/or the activity of IFP35 and/or NMI, thereby resulting in the inhibition or reduction of the expression and/or activity of an inflammatory factor, and/or resulting in the inhibition or reduction of NF-κB signaling.

### Claim 4 (depends on 3)

The method of claim 3, wherein the polynucleotide targeting the gene encoding IFP35 and/or NMI comprises an siRNA, shRNA, or miRNA.

### Claim 5 (depends on 3)

The method of claim 3, wherein the inflammatory factor comprises IL-1β, TNF-α, iNOS, and/or CD86, and the NF-κB signaling is mediated by a TLR.

### Claim 6 (depends on 5)

The method of claim 5, wherein the the NF-κB signaling is mediated by TLR4.

### Claim 7 (depends on 1)

The method of claim 1, wherein the agent comprises an antibody or antigen binding fragment that specifically binds to IFP35 and/or an antibody or antigen binding fragment that specifically binds to NMI.

### Claim 8 (depends on 7)

The method of claim 7, wherein the antibody or antigen binding fragment specifically binds to one or more NMI/IFP35 domains (NIDs).

### Claim 9 (depends on 1)

The method of claim 1, wherein the agent further comprises a pharmaceutically acceptable carrier or excipient.

### Claim 10 (depends on 1)

The method of claim 1, wherein the agent is administered via an oral, nasal, inhalational, parental, intravenous, intraperitoneal, subcutaneous, intramuscular, intradermal, topical, or rectal route.

### Claim 11 (depends on 1)

The method of claim 1, wherein the agent is administered at an amount that reduces the production and/or the activity of IFP35 and/or NMI in the subject to a level that is substantially identical to a production and/or an activity level of IFP35 and/or NMI in a comparable subject that does not have the disease or disorder associated with abnormally high level and/or activity of IFP35 and/or NMI.

### Claim 12 (depends on 1)

The method of claim 1, wherein the subject is a mammal.

### Claim 13 (depends on 12)

The method of claim 12, wherein the mammal is a human or a non-human mammal.

### Claim 14 (depends on 1)

A pharmaceutical composition for treating and/or preventing a disease or disorder associated with abnormally high level and/or activity of IFP35 and/or NMI in a subject, comprising an effective amount of the agent administered in the method according to claim 1 that prevents or reduces production and/or activity of IFP35 and/or NMI in the subject and a pharmaceutically acceptable carrier or excipient.

### Claim 15 (depends on 14)

The pharmaceutical composition of claim 14, further comprising an effective amount of a drug for the treatment and/or prevention of the disease or disorder associated with abnormally high level and/or activity of IFP35 and/or NMI in the subject.

### Claim 16

A method for identifying a modulator for Interferon-induced Protein 35 kD (IFP35) and/or N-Myc-interacting protein (NMI), comprising:
a) contacting IFP35 and/or NMI with a test substance and assessing an activity of IFP35 and/or NMI that has been contacted with the test substance;
b) assessing an activity of the IFP35 and/or NMI that has not been contacted with the test substance; and
c) comparing the activities of IFP35 and/or NMI assessed in steps a) and b), and identifying the test substance as a modulator for IFP35 and/or NMI if the activities of IFP35 and/or NMI assessed in steps a) and b) are different.

### Claim 17 (depends on 16)

The method of claim 16, wherein the test substance is a small molecule, a polypeptide library comprising mutants and/or fragments of IFP35 and/or NMI, an antibody that specifically binds to IFP35 and/or NMI, or an siRNA or an antisense RNA.

### Claim 18 (depends on 16)

The method of claim 16, wherein the method is used for identifying an inhibitor of the activity of IFP35 and/or NMI.

### Claim 19 (depends on 16)

The method of claim 16, wherein the method is used for identifying a drug for treating and/or preventing a disease or disorder associated with abnormally high level and/or activity of IFP35 and/or NMI in a subject.

### Claim 20 (depends on 16)

The method of claim 16, wherein the disease or disorder associated with abnormally high level and/or activity of IFP35 and/or NMI is a proliferation disorder, a neoplasm, a tumor, or a cancer.
